Skip to content
etf.net

BBP vs HELX

Virtus Biotech ETF

BBPANYSE Arca

Franklin Genomic Advancements ETF

HELXCCboe

Overlap

20.5%by weight

Expense ratio

BBP −0.16pt a year

BBP0.34%HELX0.50%

Avg volume · 30D

BBP 2.2×the volume

BBP11.7KHELX5.25K

5Y return · a year

BBP +17.8pt

BBP+15.2%HELX−2.6%

BBP vs HELX Performance

Nov 9, 2021 – Nov 9, 2026

+103.3%BBP−12.5%HELX

Nov 9, 2021 to Nov 9, 2026. BBP +103.3%. HELX −12.5%. Use the arrow keys to read each point.−50%25%50%75%Nov 2021May 2024Nov 2026
Expense ratio
BBP 0.34%, better
HELX 0.50%
Fund size
BBP $133M
HELX $34M
1Y total return
BBP +41.2%, better
HELX +28.7%
Yield (12M)
BBP 0.00%
HELX 0.33%, better
Holdings
BBP 66
HELX 68
Avg volume (30D)
BBP 11.7K sh, better
HELX 5.25K sh
NAV per share
BBP $102.46
HELX $42.18
52W range

ETF.net Grade

BBP: Cost 94, Risk 66, Mission 83, Tradability 29, Holdings 82, Durability 56. HELX: Cost 38, Risk 36, Mission not scored, Tradability 34, Holdings 61, Durability 43.
Pillar letters and Scores for BBP, HELX, with each pillar’s weight
PillarBBPHELX
Cost30% weightA94HigherD38
Mission25% weightA83Not scored
Risk15% weightB66HigherD36
Tradability15% weightD29D34Higher
Holdings10% weightA82HigherB61
Durability5% weightB56HigherC43

Rank among Biotech & Genomics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BBP and HELX are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds
See all 17 ›

BBP ranks 4th and HELX 13th of 17 funds in the Biotech & Genomics Category.

  1. Rank 1AXBIState Street SPDR S&P Biotech ETFScore 79
  2. Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
  3. Rank 3AIBBiShares Biotechnology ETFScore 75
  4. Rank 4ABBPVirtus Biotech ETFScore 74
  5. Rank 5BBBHVanEck Biotech ETFScore 69
  6. Rank 11CWDNAWisdomTree BioRevolution FundScore 40
  7. Rank 13CHELXFranklin Genomic Advancements ETFScore 39
  8. Rank 14DGNOMGlobal X Genomics & Biotechnology ETFScore 37

Our read on each fund

ETF.net Research

BBPAVirtus Biotech ETF

HELXCFranklin Genomic Advancements ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

HELX Most genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

HELX The Fund seeks capital appreciation.

Why people hold it

  • BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  • 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  • Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  • One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.
  • HELX A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
  • Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
  • Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
  • Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.

Worth knowing

  • BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  • Income is not the point here. The fund has not been paying distributions, so the return story is price.
  • An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.
  • HELX It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
  • The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
  • Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.

Full BBP profile⁠

Full HELX profile⁠

BBP vs HELX Holdings

How BBP and HELX differ

Overlap by weight

20.5%

Shared holdings make up 35.5% of BBP and 33.6% of HELX.

Level by level

  • Holdings21 in both20.5%
  • Sector4 Sectors96.8%
  • Countryby domicile96.8%
  • Asset classStocks100%

Sector

Sector weights in BBP and HELX, widest gap first
SectorMore in BBPMore in HELXGap
Health CareBBP +3.2 points
FinancialsHELX +2.2 points
TechnologyHELX +0.7 points
MaterialsHELX +0.4 points

Country, concentration and asset class

Country by domicile

Country weights in BBP and HELX, widest gap first
CountryMore in BBPMore in HELXGap
ChinaBBP +2.0 points
South KoreaHELX +1.1 points
GermanyHELX +0.9 points
DenmarkHELX +0.8 points
United KingdomBBP +0.7 points
Other countries (2)BBP +0.2 points

Concentration

Weight in the 10 largest Holdings

  • BBP27.9%
  • HELX46.4%

Securities held

  • BBP65
  • HELX67

Asset class

BBP
Stocks
HELX
Stocks

Holdings

  • Only in BBP44
  • In both21
  • Only in HELX46

Only in BBP

44 securities, 64.3% of BBP by weight

  • Xeris Biopharma Holdings Inc2.95%
  • Verastem Inc2.70%
  • Iovance Biotherapeutics Inc2.59%

Only in HELX

46 securities, 66.3% of HELX by weight

  • Guardant Health Inc8.65%
  • Natera Inc8.08%
  • Adaptive Biotechnologies4.92%

Weight gaps

All 21 Holdings in both funds, largest gap first.

Holding weights in BBP and HELX, widest gap first
HoldingMore in BBPMore in HELXGap
Moderna IncMRNABBP +5.86 points
Krystal Biotech IncKRYSHELX +3.60 points
Ligand Pharmaceuticals IncLGNDHELX +3.03 points
Bridgebio Pharma IncBBIOHELX +1.84 points
United Therapeutics CorpUTHRHELX +1.37 points
Rhythm Pharmaceuticals IncRYTMBBP +1.27 points
Vertex Pharmaceuticals IncVRTXHELX +1.24 points
Roivant Sciences LtdROIVBBP +1.19 points

All 198 BBP holdings⁠All 63 HELX holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BBP vs HELX Cost

Overpaying HELX vs BBP

$3,047

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBP 0.34%

    $6,932

  • HELX 0.50%

    $9,979

$10,000
30 years

Cost over time

  • BBP 0.34%
  • HELX 0.50%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530HELX $9,979BBP $6,932

Year by year

YearBBPHELXOverpaying
10$616$900$284
20$2,386$3,460$1,074
30$6,932$9,979$3,047

Expense ratio

  • 0.34%BBP, cheaper
  • 0.50%HELX
  • Middle half of Biotech & Genomics funds
  • Median 0.47%

BBP 2nd cheapest of 17 funds

HELX 10th cheapest of 17 funds

BBP vs HELX Dividends

Last 12 months to Nov 9, 2026
Yield (12M)
BBP 0.00%
HELX 0.33%, better
Payout (12M)
BBP None
HELX $0.14
Last payment
BBP No data
HELX $0.14
Ex-dividend
BBP No data
HELX Dec 30, 2025
Paid on
BBP No data
HELX Jan 8, 2026
Frequency
BBP No data
HELX Irregular

Distribution history

Per share, 2023 to 2026, same scale for both

BBPAll BBP payments⁠

No distribution history available.

HELXIrregular · 1 paymentAll HELX payments⁠
One bar per payment. 1 payment from 2023 to 2026 YTD. Dec 30, 2025 $0.14. Use the arrow keys to read each point.$0$0.1020232026YTD

BBP vs HELX Risk

Fall from peak · 5 years

  • BBP
  • HELX
Nov 9, 2021 to Nov 9, 2026. Worst fall: HELX −52.9% · Apr 2025. Use the arrow keys to read each point.−60%−40%−20%0%Nov 2021May 2024Nov 2026

Risk facts

VolatilityStd dev, 3 years
BBP 18.7%, betterHELX 20.8%
Return per unit of riskSharpe ratio, 3 years
BBP 1.30, betterHELX 0.82
Worst fallMax drawdown, 5 years
BBP −33.6%, betterHELX −52.9%
Market sensitivityBeta, 5 years
BBP 0.71HELX 0.98

Popular comparisons

  • BBPAvsXBIA

    Virtus Biotech ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.34% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • HELXCvsXBIA

    Franklin Genomic Advancements ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.50% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBQA

    Virtus Biotech ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.34% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • HELXCvsIBBQA

    Franklin Genomic Advancements ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.50% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBA

    Virtus Biotech ETF · iShares Biotechnology ETF

    Expense ratio
    0.34% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • HELXCvsIBBA

    Franklin Genomic Advancements ETF · iShares Biotechnology ETF

    Expense ratio
    0.50% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.